Status:
TERMINATED
Allopurinol in Acute Coronary Syndrome
Lead Sponsor:
Stephen McSwiggan
Collaborating Sponsors:
British Heart Foundation
Conditions:
Chronic Stable Angina
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
Allopurinol is a drug commonly used to treat gout. However recent studies have shown it has the potential to help improve oxygen supply to heart muscle. In this study the Investigators aim to find out...
Eligibility Criteria
Inclusion
- angiographically documented coronary artery disease,
- a positive exercise tolerance test (ETT)
- a history of symptoms of chronic, stable, effort-induced angina for ≥ 2 months.
- All concomitant antianginal medication will be allowed and continued unchanged during the study.
Exclusion
- the inability to do an ETT due to back or leg problems,
- myocardial infarction or acute coronary syndrome ≤ 2 months,
- coronary revascularization (percutaneous or CABG) ≤ 6 months,
- Left Ventricular Ejection Fraction \<45%,
- estimated GFR \<60 ml/min or creatinine \>180 mmol/ml,
- significant valvular pathology,
- already had gout or on allopurinol,
- atrial arrhythmias or ECG abnormalities interfering with ST-segment interpretation,
- previous ventricular arrhythmias on ETT,
- severe hepatic disease
- or on azathioprine, 6 mercaptopurine or warfarin.
- Patients who have participated in any other clinical trial within the previous 30 days will be excluded.
- Patients who are unable to give informed consent will also be excluded from this trial
Key Trial Info
Start Date :
April 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT01457820
Start Date
April 1 2012
End Date
March 1 2015
Last Update
May 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NHS Tayside
Dundee, Angus, United Kingdom, DD1 9SY